BRCA1 and breast carcinoma: Chemopreventive options are routinely offered in clinical practice given the evidence that they reduce breast cancer risk for all at-risk populations, including BRCA1/2 carriers (National Comprehensive Cancer Network (NCCN), 2021a; Gronwald et al., 2006; Narod et al., 2000).